Treatment options for patients with metastatic synovial sarcoma are limited. Over recent years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to study the efficacy of trabectedin in the subgroup of synovial sarcomas. A retrospective analysis was carried out on patients with advanced synovial sarcoma treated with trabectedin at four European reference sarcoma centers and within the Italian Rare Cancer Network between 2000 and 2013. Radiological response, progression-free, and overall survival, as well as serious and unexpected adverse events were retrospectively assessed. Sixty-one patients with metastatic synovial sarcoma were identified. The median number of previous chemotherapy regimens was 2 (range 1-6). Nine patients had a partial response, in addition to two minor responses, and 19 patients had stable disease, for an overall response rate of 15% and a tumor control rate of 50%. The median progression-free survival was 3 months, with 23% of patients free from progression at 6 months. The median progression-free survival in responding patients was 7 months. Trabectedin is a therapeutic option for palliative treatment of a subset of patients with metastatic synovial sarcoma.

Trabectedin in advanced synovial sarcomas : a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network / R. Sanfilippo, P. Dileo, J. Blay, A. Constantinidou, A. Le Cesne, C. Benson, L. Vizzini, M. Contu, G.G. Baldi, A.P. Dei Tos, P.G. Casali. - In: ANTI-CANCER DRUGS. - ISSN 0959-4973. - 26:6(2015), pp. 678-681. [10.1097/CAD.0000000000000228]

Trabectedin in advanced synovial sarcomas : a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network

P.G. Casali
Ultimo
2015

Abstract

Treatment options for patients with metastatic synovial sarcoma are limited. Over recent years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to study the efficacy of trabectedin in the subgroup of synovial sarcomas. A retrospective analysis was carried out on patients with advanced synovial sarcoma treated with trabectedin at four European reference sarcoma centers and within the Italian Rare Cancer Network between 2000 and 2013. Radiological response, progression-free, and overall survival, as well as serious and unexpected adverse events were retrospectively assessed. Sixty-one patients with metastatic synovial sarcoma were identified. The median number of previous chemotherapy regimens was 2 (range 1-6). Nine patients had a partial response, in addition to two minor responses, and 19 patients had stable disease, for an overall response rate of 15% and a tumor control rate of 50%. The median progression-free survival was 3 months, with 23% of patients free from progression at 6 months. The median progression-free survival in responding patients was 7 months. Trabectedin is a therapeutic option for palliative treatment of a subset of patients with metastatic synovial sarcoma.
chemotherapy; soft tissue sarcoma; synovial sarcoma; trabectedin; Pharmacology; Pharmacology (medical); Cancer Research; Oncology; Medicine (all)
Settore MED/06 - Oncologia Medica
2015
Article (author)
File in questo prodotto:
File Dimensione Formato  
cad-26-678.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 106.61 kB
Formato Adobe PDF
106.61 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/484358
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 44
social impact